SI0781776T1 - Water soluble rapamycin esters - Google Patents
Water soluble rapamycin estersInfo
- Publication number
- SI0781776T1 SI0781776T1 SI9630585T SI9630585T SI0781776T1 SI 0781776 T1 SI0781776 T1 SI 0781776T1 SI 9630585 T SI9630585 T SI 9630585T SI 9630585 T SI9630585 T SI 9630585T SI 0781776 T1 SI0781776 T1 SI 0781776T1
- Authority
- SI
- Slovenia
- Prior art keywords
- water soluble
- soluble rapamycin
- rapamycin esters
- esters
- water
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Polymers & Plastics (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Polyethers (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US933895P | 1995-12-27 | 1995-12-27 | |
EP96309369A EP0781776B1 (fr) | 1995-12-27 | 1996-12-20 | Esters de la rapamycine hydrosolubles |
Publications (1)
Publication Number | Publication Date |
---|---|
SI0781776T1 true SI0781776T1 (en) | 2003-06-30 |
Family
ID=21737027
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI9630585T SI0781776T1 (en) | 1995-12-27 | 1996-12-20 | Water soluble rapamycin esters |
Country Status (27)
Country | Link |
---|---|
US (2) | US5780462A (fr) |
EP (1) | EP0781776B1 (fr) |
JP (1) | JP4080560B2 (fr) |
KR (1) | KR100444003B1 (fr) |
CN (1) | CN1088710C (fr) |
AR (1) | AR005421A1 (fr) |
AT (1) | ATE233769T1 (fr) |
AU (1) | AU702750B2 (fr) |
BR (1) | BR9606173A (fr) |
CA (1) | CA2193329C (fr) |
CY (1) | CY2377B1 (fr) |
CZ (1) | CZ293711B6 (fr) |
DE (1) | DE69626481T2 (fr) |
DK (1) | DK0781776T3 (fr) |
ES (1) | ES2189858T3 (fr) |
HK (1) | HK1002864A1 (fr) |
HU (1) | HUP9603582A3 (fr) |
IL (1) | IL119921A (fr) |
MX (1) | MX9606716A (fr) |
NO (1) | NO308303B1 (fr) |
NZ (1) | NZ299974A (fr) |
PT (1) | PT781776E (fr) |
RU (1) | RU2160739C2 (fr) |
SI (1) | SI0781776T1 (fr) |
SK (1) | SK283912B6 (fr) |
TW (1) | TW403753B (fr) |
ZA (1) | ZA9610892B (fr) |
Families Citing this family (134)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1293795B1 (it) * | 1997-07-28 | 1999-03-10 | Angelini Ricerche Spa | Farmaco attivo nel ridurre la produzione di proteina mcp-1 |
US6015809A (en) * | 1998-08-17 | 2000-01-18 | American Home Products Corporation | Photocyclized rapamycin |
US7276506B2 (en) * | 1998-12-28 | 2007-10-02 | 4 Aza Bioscience Nv | Immunosuppressive effects of pteridine derivatives |
US6946465B2 (en) * | 1999-02-02 | 2005-09-20 | 4 Aza Bioscience Nv | Immunosuppressive effects of pteridine derivatives |
US6303355B1 (en) * | 1999-03-22 | 2001-10-16 | Duke University | Method of culturing, cryopreserving and encapsulating pancreatic islet cells |
US6365385B1 (en) | 1999-03-22 | 2002-04-02 | Duke University | Methods of culturing and encapsulating pancreatic islet cells |
DE60012192T2 (de) * | 1999-08-18 | 2005-09-08 | Wyeth | Wasserlösliche sdz-rad ester |
US6331547B1 (en) | 1999-08-18 | 2001-12-18 | American Home Products Corporation | Water soluble SDZ RAD esters |
WO2001068133A1 (fr) * | 2000-03-14 | 2001-09-20 | Genetics Institute, Inc. | Utilisation de la rapamycine et d'agents inhibiteurs de l'activite b7 en immunomodulation |
AU2001247401A1 (en) * | 2000-03-14 | 2001-09-24 | Genetics Institute Inc. | Therapies that improve graft survival, using antibodies against a b7 antigen |
US7300662B2 (en) * | 2000-05-12 | 2007-11-27 | Cordis Corporation | Drug/drug delivery systems for the prevention and treatment of vascular disease |
US8236048B2 (en) | 2000-05-12 | 2012-08-07 | Cordis Corporation | Drug/drug delivery systems for the prevention and treatment of vascular disease |
US6670355B2 (en) * | 2000-06-16 | 2003-12-30 | Wyeth | Method of treating cardiovascular disease |
US6511986B2 (en) | 2000-08-11 | 2003-01-28 | Wyeth | Method of treating estrogen receptor positive carcinoma |
MXPA03002258A (es) * | 2000-09-19 | 2003-06-24 | Wyeth Corp | Esteres de rapamicina solubles en agua. |
US6399625B1 (en) | 2000-09-27 | 2002-06-04 | Wyeth | 1-oxorapamycins |
JP5100951B2 (ja) | 2000-09-29 | 2012-12-19 | コーディス・コーポレイション | 被覆医用器具 |
US6440991B1 (en) | 2000-10-02 | 2002-08-27 | Wyeth | Ethers of 7-desmethlrapamycin |
US6399626B1 (en) | 2000-10-02 | 2002-06-04 | Wyeth | Hydroxyesters of 7-desmethylrapamycin |
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
ES2544624T3 (es) | 2002-07-16 | 2015-09-02 | Buck Institute For Research On Aging | Producción de policétidos |
BR0313024A (pt) | 2002-07-30 | 2005-07-12 | Wyeth Corp | Formulações parenterais contendo um hidroxiéster de rapamicina |
EP1615669A2 (fr) * | 2003-04-23 | 2006-01-18 | Wyeth Holdings Corporation | Conjugues de wortmannine avec peg |
WO2005025574A2 (fr) * | 2003-09-12 | 2005-03-24 | 4 Aza Bioscience Nv | Derives de pteridine pour le traitement du choc septique et de maladies liees au tnf-$g(a) |
US20070032477A1 (en) * | 2003-10-17 | 2007-02-08 | Waer Mark J A | Pteridine derivatives useful for making pharmaceutical compositions |
JP2007532655A (ja) * | 2004-04-14 | 2007-11-15 | ワイス | ラパマイシンコンジュゲートおよび抗体のための前駆体である、ジカルボン酸とのラパマイシン42−エステルおよびジカルボン酸とのfk−50632−エステルの調製プロセス |
AU2005238431A1 (en) | 2004-04-14 | 2005-11-10 | Wyeth | Regiospecific synthesis of rapamycin 42-ester derivatives |
MXPA06012404A (es) * | 2004-04-27 | 2007-01-17 | Wyeth Corp | Marcado de rapamicina usando metilasas especificas de rapamicina. |
GB0417852D0 (en) | 2004-08-11 | 2004-09-15 | Biotica Tech Ltd | Production of polyketides and other natural products |
US8313763B2 (en) * | 2004-10-04 | 2012-11-20 | Tolmar Therapeutics, Inc. | Sustained delivery formulations of rapamycin compounds |
MX2007003789A (es) * | 2004-10-04 | 2007-07-20 | Qlt Usa Inc | Suministro ocular de formulaciones polimericas para suministro. |
MX2007005153A (es) * | 2004-10-28 | 2007-06-26 | Wyeth Corp | Uso de un inhibidor del mtor en el tratamiento de leiomioma del utero. |
GB0428475D0 (en) * | 2004-12-30 | 2005-02-02 | 4 Aza Bioscience Nv | Pyrido(3,2-D)pyrimidine derivatives and pharmaceutical compositions useful as medicines for the treatment of autoimmune disorders |
GB0503936D0 (en) * | 2005-02-25 | 2005-04-06 | San Raffaele Centro Fond | Method |
US20100047338A1 (en) | 2008-03-14 | 2010-02-25 | Angela Brodie | Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity |
CA2602010A1 (fr) | 2005-03-07 | 2006-09-14 | Wyeth | Isomere d'oxepane du 42-o-(2-hydroxy)ethyl-rapamycine |
GB0504994D0 (en) | 2005-03-11 | 2005-04-20 | Biotica Tech Ltd | Novel compounds |
US20100061994A1 (en) * | 2005-03-11 | 2010-03-11 | Rose Mary Sheridan | Medical uses of 39-desmethoxyrapamycin and analogues thereof |
CA2599547A1 (fr) | 2005-03-11 | 2006-09-14 | Biotica Technology Limited | Utilisation d'un compose |
AU2006261607A1 (en) * | 2005-06-24 | 2006-12-28 | Gilead Sciences, Inc. | Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for treating hepatitis C. |
DK2298815T3 (en) | 2005-07-25 | 2015-06-15 | Emergent Product Dev Seattle | B-CELL REDUCTION USING CD37 SPECIFIC AND CD20 SPECIFIC BINDING MOLECULES |
EP3488866A1 (fr) | 2005-11-04 | 2019-05-29 | Wyeth LLC | Combinaisons antinéoplasiques avec inhibiteur de mtor, d'herceptine et/ou hki-272 |
AU2006331874A1 (en) * | 2005-12-20 | 2007-07-05 | Wyeth | Control of CCI-779 dosage form stability through control of drug substance impurities |
JP2009529050A (ja) * | 2006-03-07 | 2009-08-13 | ワイス | マクロライド免疫抑制剤の水溶性ポリエチレングリコール複合体を調製するためのプロセス |
GB0609962D0 (en) * | 2006-05-19 | 2006-06-28 | Biotica Tech Ltd | Novel compounds |
GB0609963D0 (en) * | 2006-05-19 | 2006-06-28 | Biotica Tech Ltd | Novel compounds |
US8338435B2 (en) * | 2006-07-20 | 2012-12-25 | Gilead Sciences, Inc. | Substituted pyrido(3,2-D) pyrimidines and pharmaceutical compositions for treating viral infections |
US10144736B2 (en) * | 2006-07-20 | 2018-12-04 | Gilead Sciences, Inc. | Substituted pteridines useful for the treatment and prevention of viral infections |
US20080051691A1 (en) * | 2006-08-28 | 2008-02-28 | Wyeth | Implantable shunt or catheter enabling gradual delivery of therapeutic agents |
TW200824713A (en) * | 2006-10-18 | 2008-06-16 | Wyeth Corp | Processes for the synthesis of individual isomers of mono-PEG CCI-779 |
US8414910B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Drug releasing coatings for medical devices |
US8414525B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Drug releasing coatings for medical devices |
US8414526B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids |
US8425459B2 (en) | 2006-11-20 | 2013-04-23 | Lutonix, Inc. | Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent |
US8414909B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Drug releasing coatings for medical devices |
US9737640B2 (en) | 2006-11-20 | 2017-08-22 | Lutonix, Inc. | Drug releasing coatings for medical devices |
US9700704B2 (en) | 2006-11-20 | 2017-07-11 | Lutonix, Inc. | Drug releasing coatings for balloon catheters |
US20080276935A1 (en) | 2006-11-20 | 2008-11-13 | Lixiao Wang | Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs |
US8998846B2 (en) | 2006-11-20 | 2015-04-07 | Lutonix, Inc. | Drug releasing coatings for balloon catheters |
US8440185B2 (en) * | 2006-12-26 | 2013-05-14 | The Johns Hopkins University | Compositions and methods for the treatment of immunologic disorders |
TW200840584A (en) * | 2006-12-26 | 2008-10-16 | Gilead Sciences Inc | Pyrido(3,2-d)pyrimidines useful for treating viral infections |
EP2109455A2 (fr) * | 2006-12-27 | 2009-10-21 | The Johns Hopkins University | Compositions et procédés pour la stimulation d'une réaction immunitaire |
US7989173B2 (en) | 2006-12-27 | 2011-08-02 | The Johns Hopkins University | Detection and diagnosis of inflammatory disorders |
US20090142342A1 (en) * | 2006-12-27 | 2009-06-04 | Johns Hopkins University | B7-h4 receptor agonist compositions and methods for treating inflammation and auto-immune diseases |
TW200845960A (en) * | 2007-04-05 | 2008-12-01 | Wyeth Corp | Wortmannin-rapalog conjugate and uses thereof |
TW200901989A (en) | 2007-04-10 | 2009-01-16 | Wyeth Corp | Anti-tumor activity of CCI-779 in papillary renal cell cancer |
AU2009225434B2 (en) | 2008-03-21 | 2014-05-22 | The University Of Chicago | Treatment with opioid antagonists and mTOR inhibitors |
ES2368700T3 (es) | 2008-04-11 | 2011-11-21 | Emergent Product Development Seattle, Llc | Agente inmunoterapéutico para cd37 y combinación con un agente quimioterapéutico bifuncional del mismo. |
US20110098241A1 (en) * | 2008-04-14 | 2011-04-28 | Poniard Pharmaceuticals, Inc. | Rapamycin analogs as anti-cancer agents |
WO2010024898A2 (fr) | 2008-08-29 | 2010-03-04 | Lutonix, Inc. | Procédés et appareils pour poser un revêtement sur des cathéters à ballonnet |
CA2937492C (fr) | 2008-11-11 | 2019-08-13 | The Board Of Regents Of The University Of Texas System | Inhibition de cible mammalienne de rapamycine |
AU2010210422A1 (en) | 2009-02-05 | 2011-08-18 | Tokai Pharmaceuticals, Inc. | Novel prodrugs of steroidal CYP17 inhibitors/antiandrogens |
ES2665277T3 (es) | 2009-03-13 | 2018-04-25 | Katholieke Universiteit Leuven K.U. Leuven R&D | Análogos de purina y su uso como agentes inmunosupresores |
WO2010114616A1 (fr) * | 2009-04-03 | 2010-10-07 | The University Of Toledo | Composition peg-albumine ayant au moins une région thiol protégée en tant que plateforme pour des médicaments |
IN2012DN02753A (fr) | 2009-08-31 | 2015-09-18 | Amplimmune Inc | |
CN102770129A (zh) | 2009-10-30 | 2012-11-07 | 阿里亚德医药股份有限公司 | 治疗癌症的方法和组合物 |
US9283211B1 (en) | 2009-11-11 | 2016-03-15 | Rapamycin Holdings, Llc | Oral rapamycin preparation and use for stomatitis |
WO2011109833A2 (fr) | 2010-03-05 | 2011-09-09 | President And Fellows Of Harvard College | Compositions de cellules dendritiques induites et utilisations associées |
MX342590B (es) | 2010-04-27 | 2016-10-05 | Roche Glycart Ag | Terapia de combinacion de un anticuerpo cd20 afucosilado con un inhibidor mtor. |
GB201012889D0 (en) | 2010-08-02 | 2010-09-15 | Univ Leuven Kath | Antiviral activity of novel bicyclic heterocycles |
GB201015411D0 (en) | 2010-09-15 | 2010-10-27 | Univ Leuven Kath | Anti-cancer activity of novel bicyclic heterocycles |
JP2014519813A (ja) | 2011-04-25 | 2014-08-21 | オーエスアイ・ファーマシューティカルズ,エルエルシー | 癌薬剤発見、診断、および治療におけるemt遺伝子シグネチャーの使用 |
EP2532740A1 (fr) | 2011-06-11 | 2012-12-12 | Michael Schmück | Préparations de lymphocytes T à mémoire centrale CD4+ et CD8+ spécifiques aux antigènes pour thérapie de lymphocyte T adoptif |
WO2013013708A1 (fr) | 2011-07-26 | 2013-01-31 | Fundació Institut D'investigació Biomèdica De Bellvitge | Traitement du rejet aigu dans une transplantation rénale |
GB201115665D0 (en) | 2011-09-09 | 2011-10-26 | Univ Leuven Kath | Autoimmune and inflammatory disorder therapy |
GB201122305D0 (en) | 2011-12-23 | 2012-02-01 | Biotica Tech Ltd | Novel compound |
EP3939572B1 (fr) | 2012-04-12 | 2024-03-27 | Yale University | Véhicules pour l'administration contrôlée d'agents pharmaceutiques différents |
CN103705925B (zh) | 2012-09-29 | 2018-03-30 | 段磊 | 抑制PI3K/AKT/mTOR信号通路的药物组合 |
US9750728B2 (en) | 2012-09-29 | 2017-09-05 | Targeted Therapeutics, Llc | Method and pharmaceutical composition for inhibiting PI3K/AKT/mTOR signaling pathway |
WO2014059295A1 (fr) | 2012-10-12 | 2014-04-17 | The Board Of Regents Of The University Of Texas System | Utilisation d'inhibiteurs mtor pour traiter le déficit cognitif vasculaire |
EP2914260A1 (fr) | 2012-10-31 | 2015-09-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Procédés pour prévenir le syndrome des antiphospholipides (sapl) |
EP2934575A2 (fr) | 2012-12-19 | 2015-10-28 | Amplimmune, Inc. | Anticorps spécifiques de b7-h4, compositions et utilisations de ceux-ci |
WO2014160328A1 (fr) | 2013-03-13 | 2014-10-02 | The Board Of Regents Of The University Of Texas System | Inhibiteurs de mtor pour la prévention de la croissance de polypes intestinaux |
CA2904170A1 (fr) | 2013-03-14 | 2014-09-25 | University Of Maryland, Baltimore | Agents de diminution du recepteur des androgenes et leurs utilisations |
US20160146806A1 (en) | 2013-05-17 | 2016-05-26 | Amplimmune, Inc. | Receptors for b7-h4 |
WO2015023710A1 (fr) | 2013-08-12 | 2015-02-19 | Tokai Pharmaceuticals, Inc. | Biomarqueurs pour le traitement de troubles néoplasiques à l'aide de thérapies ciblant les androgènes |
US9700544B2 (en) | 2013-12-31 | 2017-07-11 | Neal K Vail | Oral rapamycin nanoparticle preparations |
AU2014373683B2 (en) | 2013-12-31 | 2020-05-07 | Rapamycin Holdings, Llc | Oral rapamycin nanoparticle preparations and use |
EP3122376A4 (fr) | 2014-03-27 | 2017-12-20 | The Brigham and Women's Hospital, Inc. | Conjugués de médicaments activés métaboliquement pour vaincre la résistance dans une thérapie du cancer |
EP3131546B1 (fr) | 2014-04-16 | 2022-02-16 | Rapamycin Holdings, Inc. | Préparation orale de rapamycine pour utilisation dans le traitement de la gingivo-stomatite chronique féline (fcgs) |
EP3148564B1 (fr) | 2014-06-02 | 2020-01-08 | Children's Medical Center Corporation | Procédés et compositions pour une immunomodulation |
WO2016040806A1 (fr) | 2014-09-11 | 2016-03-17 | The Regents Of The University Of California | Inhibiteurs de mtorc1 |
UA123090C2 (uk) | 2015-03-04 | 2021-02-17 | Гіліад Сайєнсіз, Інк. | 4,6-ДІАМІНОПІРИДО[3,2-d]ПІРИМІДИНОВІ СПОЛУКИ, ЯКІ МОДУЛЮЮТЬ TOLL-ПОДІБНІ РЕЦЕПТОРИ |
WO2017029391A1 (fr) | 2015-08-20 | 2017-02-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Nouvelle méthode de traitement du cancer |
ES2957882T3 (es) | 2015-09-04 | 2024-01-29 | Univ Yale | Nanocomposiciones de ácidos biliares poliméricos dirigidas al páncreas y al colon |
US20190117799A1 (en) | 2016-04-01 | 2019-04-25 | The Brigham And Women's Hospital, Inc. | Stimuli-responsive nanoparticles for biomedical applications |
RU2757394C2 (ru) | 2016-08-03 | 2021-10-14 | Нексткьюр, Инк. | Композиции и способы для модуляции передачи сигнала lair |
WO2018045150A1 (fr) | 2016-09-02 | 2018-03-08 | Gilead Sciences, Inc. | Dérivés de 4,6-diamino-pyrido [3,2-d] pyrimidine en tant que modulateurs du récepteur de type toll |
EP3507276B1 (fr) | 2016-09-02 | 2021-11-03 | Gilead Sciences, Inc. | Composés modulateurs du recepteur de type toll |
EP4360714A2 (fr) | 2016-09-21 | 2024-05-01 | Nextcure, Inc. | Anticorps pour siglec-15 et leurs procédés d'utilisation |
US11390675B2 (en) | 2016-09-21 | 2022-07-19 | Nextcure, Inc. | Antibodies for Siglec-15 and methods of use thereof |
GB201701087D0 (en) | 2017-01-23 | 2017-03-08 | Univ Leuven Kath | Novel prodrugs of mizoribine |
CN110603038A (zh) | 2017-02-10 | 2019-12-20 | 塔姆山治疗公司 | 雷帕霉素类似物 |
EP3848065B1 (fr) | 2017-05-15 | 2023-07-26 | C. R. Bard, Inc. | Dispositif médical à revêtement d'élution de médicament et à couche intermédiaire |
WO2019002168A1 (fr) | 2017-06-26 | 2019-01-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Méthodes et compositions pharmaceutiques de traitement du syndrome d'olmsted |
JP2020527044A (ja) | 2017-07-13 | 2020-09-03 | アンセルム(アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル) | CD8+CD45RCLOW/−Treg集団の拡大増殖および免疫抑制能力を高めるための方法 |
SG11202010559UA (en) | 2018-05-01 | 2020-11-27 | Revolution Medicines Inc | C40-, c28-, and c-32-linked rapamycin analogs as mtor inhibitors |
SG11202010560QA (en) | 2018-05-01 | 2020-11-27 | Revolution Medicines Inc | C26-linked rapamycin analogs as mtor inhibitors |
US20210115378A1 (en) | 2018-05-09 | 2021-04-22 | Yale University | Compositions and systems for ex vivo cell modulation and methods of use thereof |
WO2019217552A1 (fr) | 2018-05-09 | 2019-11-14 | Yale University | Particules pour la libération spatio-temporelle d'agents |
AU2019310039A1 (en) | 2018-07-23 | 2021-02-18 | Enclear Therapies, Inc. | Methods of treating neurological disorders |
AU2019310040A1 (en) | 2018-07-23 | 2021-02-11 | Enclear Therapies, Inc. | Methods of treating neurological disorders |
WO2020053125A1 (fr) | 2018-09-10 | 2020-03-19 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Procédés de traitement de la neurofibromatose |
US11541152B2 (en) | 2018-11-14 | 2023-01-03 | Lutonix, Inc. | Medical device with drug-eluting coating on modified device surface |
EP3911302A1 (fr) | 2019-01-17 | 2021-11-24 | Georgia Tech Research Corporation | Systèmes d'administration de médicament contenant des cholestérols oxydés |
JP7487228B2 (ja) | 2019-04-08 | 2024-05-20 | バード・ペリフェラル・バスキュラー・インコーポレーテッド | 改質されたデバイス表面に薬物溶出コーティングを有する医療用デバイス |
KR20220011123A (ko) | 2019-04-11 | 2022-01-27 | 엔클리어 테라피스, 인크. | 뇌척수액 개선 방법 및 이를 위한 디바이스 및 시스템 |
TW202210480A (zh) | 2019-04-17 | 2022-03-16 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
TWI751517B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
TW202115056A (zh) | 2019-06-28 | 2021-04-16 | 美商基利科學股份有限公司 | 類鐸受體調節劑化合物的製備方法 |
EP4167958A1 (fr) | 2020-06-19 | 2023-04-26 | Yale University | Nanoparticules d'ester d'acide biliaire polymère comprenant un agent immunomodulateur pour induire une tolérance spécifique à l'antigène |
EP4370160A1 (fr) | 2021-07-15 | 2024-05-22 | President And Fellows Of Harvard College | Compositions et méthodes associées à des cellules comprenant des particules adhérées |
WO2024008799A1 (fr) | 2022-07-06 | 2024-01-11 | Institut National de la Santé et de la Recherche Médicale | Méthodes de traitement de la glomérulonéphrite proliférative |
WO2024028433A1 (fr) | 2022-08-04 | 2024-02-08 | Institut National de la Santé et de la Recherche Médicale | Procédés de traitement de troubles lymphoprolifératifs |
Family Cites Families (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA737247B (en) * | 1972-09-29 | 1975-04-30 | Ayerst Mckenna & Harrison | Rapamycin and process of preparation |
US3993749A (en) * | 1974-04-12 | 1976-11-23 | Ayerst Mckenna And Harrison Ltd. | Rapamycin and process of preparation |
US4885171A (en) * | 1978-11-03 | 1989-12-05 | American Home Products Corporation | Use of rapamycin in treatment of certain tumors |
US4684728A (en) * | 1979-01-12 | 1987-08-04 | Bayer Aktiengesellschaft | Solubilizing biologically active compounds with reactive hydrogen atoms |
US4316885A (en) * | 1980-08-25 | 1982-02-23 | Ayerst, Mckenna And Harrison, Inc. | Acyl derivatives of rapamycin |
US4401653A (en) * | 1981-03-09 | 1983-08-30 | Ayerst, Mckenna & Harrison Inc. | Combination of rapamycin and picibanil for the treatment of tumors |
US4375464A (en) * | 1981-11-19 | 1983-03-01 | Ayerst, Mckenna & Harrison Inc. | Antibiotic AY24,668 and process of preparation |
EP0429436A3 (en) * | 1985-12-06 | 1991-12-27 | The University Of Kansas | Prodrugs of rapamycin |
US4650803A (en) * | 1985-12-06 | 1987-03-17 | University Of Kansas | Prodrugs of rapamycin |
JP2631710B2 (ja) | 1988-08-16 | 1997-07-16 | 日本ヘキスト・マリオン・ルセル株式会社 | ピラノ〔f〕キノリノン誘導体及び該化合物を有効成分とする医薬組成物 |
US5100899A (en) * | 1989-06-06 | 1992-03-31 | Roy Calne | Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof |
US5023264A (en) * | 1990-07-16 | 1991-06-11 | American Home Products Corporation | Rapamycin oximes |
US5023263A (en) * | 1990-08-09 | 1991-06-11 | American Home Products Corporation | 42-oxorapamycin |
US5023262A (en) * | 1990-08-14 | 1991-06-11 | American Home Products Corporation | Hydrogenated rapamycin derivatives |
US5221670A (en) * | 1990-09-19 | 1993-06-22 | American Home Products Corporation | Rapamycin esters |
US5130307A (en) * | 1990-09-28 | 1992-07-14 | American Home Products Corporation | Aminoesters of rapamycin |
US5378696A (en) * | 1990-09-19 | 1995-01-03 | American Home Products Corporation | Rapamycin esters |
PT98990A (pt) * | 1990-09-19 | 1992-08-31 | American Home Prod | Processo para a preparacao de esteres de acidos carboxilicos de rapamicina |
US5233036A (en) * | 1990-10-16 | 1993-08-03 | American Home Products Corporation | Rapamycin alkoxyesters |
US5078999A (en) * | 1991-02-22 | 1992-01-07 | American Home Products Corporation | Method of treating systemic lupus erythematosus |
US5080899A (en) * | 1991-02-22 | 1992-01-14 | American Home Products Corporation | Method of treating pulmonary inflammation |
US5120842A (en) * | 1991-04-01 | 1992-06-09 | American Home Products Corporation | Silyl ethers of rapamycin |
US5321009A (en) * | 1991-04-03 | 1994-06-14 | American Home Products Corporation | Method of treating diabetes |
IL101353A0 (en) * | 1991-04-03 | 1992-11-15 | American Home Prod | Pharmaceutical compositions for treating diabetes |
US5100883A (en) * | 1991-04-08 | 1992-03-31 | American Home Products Corporation | Fluorinated esters of rapamycin |
US5118678A (en) * | 1991-04-17 | 1992-06-02 | American Home Products Corporation | Carbamates of rapamycin |
US5194447A (en) * | 1992-02-18 | 1993-03-16 | American Home Products Corporation | Sulfonylcarbamates of rapamycin |
US5093338A (en) | 1991-04-23 | 1992-03-03 | Merck & Co., Inc. | Lipophilic macrolide useful as an immunosuppressant |
US5091389A (en) * | 1991-04-23 | 1992-02-25 | Merck & Co., Inc. | Lipophilic macrolide useful as an immunosuppressant |
US5138051A (en) * | 1991-08-07 | 1992-08-11 | American Home Products Corporation | Rapamycin analogs as immunosuppressants and antifungals |
US5102876A (en) * | 1991-05-07 | 1992-04-07 | American Home Products Corporation | Reduction products of rapamycin |
US5118677A (en) * | 1991-05-20 | 1992-06-02 | American Home Products Corporation | Amide esters of rapamycin |
CA2102116A1 (fr) * | 1991-05-31 | 1992-12-01 | Gary R. Schulte | Utilisation de precurseurs de la rapamycine comme agents immunosuppresseurs |
SG43072A1 (en) * | 1991-06-18 | 1997-10-17 | American Home Prod | Method of treating adult t-cell leukemia/lymphoma |
ZA924953B (en) * | 1991-07-25 | 1993-04-28 | Univ Louisville Res Found | Method of treating ocular inflammation |
US5169851A (en) * | 1991-08-07 | 1992-12-08 | American Home Products Corporation | Rapamycin analog as immunosuppressants and antifungals |
US5151413A (en) * | 1991-11-06 | 1992-09-29 | American Home Products Corporation | Rapamycin acetals as immunosuppressant and antifungal agents |
US5516781A (en) * | 1992-01-09 | 1996-05-14 | American Home Products Corporation | Method of treating restenosis with rapamycin |
US5177203A (en) * | 1992-03-05 | 1993-01-05 | American Home Products Corporation | Rapamycin 42-sulfonates and 42-(N-carboalkoxy) sulfamates useful as immunosuppressive agents |
ATE193652T1 (de) * | 1992-03-30 | 2000-06-15 | American Home Prod | Rapamycin formulierung zur iv-injektion |
US5256790A (en) | 1992-08-13 | 1993-10-26 | American Home Products Corporation | 27-hydroxyrapamycin and derivatives thereof |
GB9221220D0 (en) * | 1992-10-09 | 1992-11-25 | Sandoz Ag | Organic componds |
US5302584A (en) * | 1992-10-13 | 1994-04-12 | American Home Products Corporation | Carbamates of rapamycin |
US5258389A (en) * | 1992-11-09 | 1993-11-02 | Merck & Co., Inc. | O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives |
US5260300A (en) * | 1992-11-19 | 1993-11-09 | American Home Products Corporation | Rapamycin carbonate esters as immuno-suppressant agents |
US5516770A (en) * | 1993-09-30 | 1996-05-14 | American Home Products Corporation | Rapamycin formulation for IV injection |
US5391730A (en) * | 1993-10-08 | 1995-02-21 | American Home Products Corporation | Phosphorylcarbamates of rapamycin and oxime derivatives thereof |
US5385909A (en) * | 1993-11-22 | 1995-01-31 | American Home Products Corporation | Heterocyclic esters of rapamycin |
US5385908A (en) * | 1993-11-22 | 1995-01-31 | American Home Products Corporation | Hindered esters of rapamycin |
US5385910A (en) * | 1993-11-22 | 1995-01-31 | American Home Products Corporation | Gem-distributed esters of rapamycin |
US5389639A (en) * | 1993-12-29 | 1995-02-14 | American Home Products Company | Amino alkanoic esters of rapamycin |
US5362718A (en) * | 1994-04-18 | 1994-11-08 | American Home Products Corporation | Rapamycin hydroxyesters |
US5463048A (en) * | 1994-06-14 | 1995-10-31 | American Home Products Corporation | Rapamycin amidino carbamates |
US5491231A (en) * | 1994-11-28 | 1996-02-13 | American Home Products Corporation | Hindered N-oxide esters of rapamycin |
US5563145A (en) * | 1994-12-07 | 1996-10-08 | American Home Products Corporation | Rapamycin 42-oximes and hydroxylamines |
US5496832A (en) * | 1995-03-09 | 1996-03-05 | American Home Products Corporation | Method of treating cardiac inflammatory disease |
-
1996
- 1996-12-11 US US08/763,768 patent/US5780462A/en not_active Expired - Lifetime
- 1996-12-18 CA CA002193329A patent/CA2193329C/fr not_active Expired - Fee Related
- 1996-12-18 CZ CZ19963734A patent/CZ293711B6/cs not_active IP Right Cessation
- 1996-12-19 MX MX9606716A patent/MX9606716A/es not_active IP Right Cessation
- 1996-12-19 NZ NZ299974A patent/NZ299974A/en unknown
- 1996-12-19 SK SK1638-96A patent/SK283912B6/sk unknown
- 1996-12-20 EP EP96309369A patent/EP0781776B1/fr not_active Expired - Lifetime
- 1996-12-20 SI SI9630585T patent/SI0781776T1/xx unknown
- 1996-12-20 PT PT96309369T patent/PT781776E/pt unknown
- 1996-12-20 AT AT96309369T patent/ATE233769T1/de not_active IP Right Cessation
- 1996-12-20 DK DK96309369T patent/DK0781776T3/da active
- 1996-12-20 ES ES96309369T patent/ES2189858T3/es not_active Expired - Lifetime
- 1996-12-20 DE DE69626481T patent/DE69626481T2/de not_active Expired - Fee Related
- 1996-12-20 HU HU9603582A patent/HUP9603582A3/hu unknown
- 1996-12-23 AU AU76517/96A patent/AU702750B2/en not_active Ceased
- 1996-12-23 NO NO965552A patent/NO308303B1/no unknown
- 1996-12-23 ZA ZA9610892A patent/ZA9610892B/xx unknown
- 1996-12-24 CN CN96123983A patent/CN1088710C/zh not_active Expired - Fee Related
- 1996-12-24 TW TW085115988A patent/TW403753B/zh not_active IP Right Cessation
- 1996-12-24 KR KR1019960071130A patent/KR100444003B1/ko not_active IP Right Cessation
- 1996-12-25 RU RU96124399/04A patent/RU2160739C2/ru not_active IP Right Cessation
- 1996-12-26 JP JP34739396A patent/JP4080560B2/ja not_active Expired - Fee Related
- 1996-12-26 AR ARP960105902A patent/AR005421A1/es active IP Right Grant
- 1996-12-26 BR BR9606173A patent/BR9606173A/pt not_active IP Right Cessation
- 1996-12-26 IL IL11992196A patent/IL119921A/xx not_active IP Right Cessation
-
1998
- 1998-03-10 HK HK98101959A patent/HK1002864A1/xx not_active IP Right Cessation
- 1998-03-23 US US09/046,043 patent/US5955457A/en not_active Expired - Fee Related
-
2003
- 2003-09-10 CY CY0300062A patent/CY2377B1/xx unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HU9603582D0 (en) | Water soluble rapamycin esters | |
HK1014949A1 (en) | Rapamycin derivatives | |
AP9801250A0 (en) | Water disalination | |
HUP9900429A3 (en) | Expandible stent | |
NZ307170A (en) | Ascomycin derivatives | |
EP0816571A4 (fr) | Fondation | |
GB9521805D0 (en) | Solubilisation methods | |
GB9617204D0 (en) | Roulette | |
PL322308A1 (en) | Automatic drawing-bench | |
EP0754668A3 (fr) | Dérivés de l'éther fluoro-benzylique | |
IL125063A0 (en) | Water soluble antibiotics | |
GB2305617B (en) | Water filtering | |
GB2303409A8 (en) | Turbine | |
GB2300675B (en) | Turbines | |
GB9525077D0 (en) | Esters | |
GB9525417D0 (en) | Esters | |
EP0821767A4 (fr) | Element de retenue | |
GB9523183D0 (en) | Turbines | |
SI0833828T1 (en) | Rapamycin derivatives | |
BG99800U (en) | Chessboard set | |
IL114435A0 (en) | Water turbine | |
GB9511709D0 (en) | Drainage component | |
GB9510980D0 (en) | Level | |
GB9514253D0 (en) | All-ways level | |
GB9516823D0 (en) | Roulette |